Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Tarpgaard LS, Christensen IJ, Høyer-Hansen G, Lund IK, Guren TK, Glimelius B, Sorbye H, Tveit KM, Nielsen HJ, Moreira JM, Pfeiffer P, Brünner N. Tarpgaard LS, et al. Among authors: moreira jm. Int J Cancer. 2015 Nov 15;137(10):2470-7. doi: 10.1002/ijc.29476. Epub 2015 Mar 9. Int J Cancer. 2015. PMID: 25664394 Free article. Clinical Trial.
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM. Tarpgaard LS, et al. Among authors: moreira jm. Oncotarget. 2016 Sep 13;7(37):59441-59457. doi: 10.18632/oncotarget.11118. Oncotarget. 2016. PMID: 27509063 Free PMC article. Clinical Trial.
Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.
Jensen NF, Stenvang J, Beck MK, Hanáková B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, Tarpgaard LS, Hansen TP, Budinská E, Pfeiffer P, Bosman F, Tejpar S, Roth A, Delorenzi M, Andersen CL, Rømer MU, Brünner N, Moreira JM. Jensen NF, et al. Among authors: moreira jm. Mol Oncol. 2015 Jun;9(6):1169-85. doi: 10.1016/j.molonc.2015.02.008. Epub 2015 Feb 24. Mol Oncol. 2015. PMID: 25759163 Free PMC article.
Purification and characterization of bioactive his6-tagged recombinant human tissue inhibitor of metalloproteinases-1 (TIMP-1) protein expressed at high yields in mammalian cells.
Vinther L, Lademann U, Andersen EV, Højrup P, Thaysen-Andersen M, Krogh BO, Viuff B, Brünner N, Stenvang J, Moreira JM. Vinther L, et al. Among authors: moreira jm. Protein Expr Purif. 2014 Sep;101:157-64. doi: 10.1016/j.pep.2014.06.013. Epub 2014 Jul 3. Protein Expr Purif. 2014. PMID: 24998777
Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research.
Celis JE, Gromov P, Gromova I, Moreira JM, Cabezón T, Ambartsumian N, Grigorian M, Lukanidin E, Thor Straten P, Guldberg P, Bartkova J, Bartek J, Lukas J, Lukas C, Lykkesfeldt A, Jäättelä M, Roepstorff P, Bolund L, Ørntoft T, Brünner N, Overgaard J, Sandelin K, Blichert-Toft M, Mouridsen H, Rank FE. Celis JE, et al. Among authors: moreira jm. Mol Cell Proteomics. 2003 Jun;2(6):369-77. doi: 10.1074/mcp.R300007-MCP200. Epub 2003 Jun 25. Mol Cell Proteomics. 2003. PMID: 12832461 Free article.
Towards discovery-driven translational research in breast cancer.
Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, Straten PT, Mouridsen H, Friis E, Holm D, Rank F, Gromov P. Celis JE, et al. Among authors: moreira jm. FEBS J. 2005 Jan;272(1):2-15. doi: 10.1111/j.1432-1033.2004.04418.x. FEBS J. 2005. PMID: 15634327 Free article. Review.
127 results